Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Fang

Showing results (281-290 of 300) with videos related to

Pageof 30
Sort By:
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Cancers|February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic CancerYung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Acta Cardiologica Sinica|May 31, 2018
2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in TaiwanYi-Heng Li, Chih-Yuan Fang, I-Chang Hsieh, et al.
Journal of the Chinese Medical Association : JCMA|December 15, 2025
Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trialChien-Hsing Wu, Chih-Chung Shiao, Hsien-Yi Wang, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Pageof 30

Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Cancers|February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic CancerYung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Acta Cardiologica Sinica|May 31, 2018
2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in TaiwanYi-Heng Li, Chih-Yuan Fang, I-Chang Hsieh, et al.
Journal of the Chinese Medical Association : JCMA|December 15, 2025
Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trialChien-Hsing Wu, Chih-Chung Shiao, Hsien-Yi Wang, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Pageof 30